Literature DB >> 29409840

Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions.

Austin L Daniels1, Theodore W Randolph2.   

Abstract

The presence of subvisible particles in formulations of therapeutic proteins is a risk factor for adverse immune responses. Although the immunogenic potential of particulate contaminants likely depends on particle structural characteristics (e.g., composition, size, and shape), exact structure-immunogenicity relationships are unknown. Images recorded by flow imaging microscopy reflect information about particle morphology, but flow microscopy is typically used to determine only particle size distributions, neglecting information on particle morphological features that may be immunologically relevant. We recently developed computational techniques that utilize the Kullback-Leibler divergence and multidimensional scaling to compare the morphological properties of particles in sets of flow microscopy images. In the current work, we combined these techniques with expectation maximization cluster analyses and used them to compare flow imaging microscopy data sets that had been collected by the U.S. Food and Drug Administration after severe adverse drug reactions (including 7 fatalities) were observed in patients who had been administered some lots of peginesatide formulations. Flow microscopy images of particle populations found in the peginesatide lots associated with severe adverse reactions in patients were readily distinguishable from images of particles in lots where severe adverse reactions did not occur.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  image analysis; protein aggregation; protein formulation; regulatory science

Mesh:

Substances:

Year:  2018        PMID: 29409840      PMCID: PMC5916335          DOI: 10.1016/j.xphs.2018.01.015

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  49 in total

Review 1.  Immunogenicity of protein aggregates--concerns and realities.

Authors:  Wei Wang; Satish K Singh; Ning Li; Maria R Toler; Kevin R King; Sandeep Nema
Journal:  Int J Pharm       Date:  2012-04-21       Impact factor: 5.875

2.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models.

Authors:  Amber Haynes Fradkin; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2009-09       Impact factor: 3.534

3.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

4.  Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene.

Authors:  Miranda M C Van Beers; Francesca Gilli; Huub Schellekens; Theodore W Randolph; Wim Jiskoot
Journal:  J Pharm Sci       Date:  2011-09-14       Impact factor: 3.534

5.  Microflow Imaging Analyses Reflect Mechanisms of Aggregate Formation: Comparing Protein Particle Data Sets Using the Kullback-Leibler Divergence.

Authors:  Nathaniel R Maddux; Austin L Daniels; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2017-02-01       Impact factor: 3.534

6.  Biopharmaceutical benchmarks 2014.

Authors:  Gary Walsh
Journal:  Nat Biotechnol       Date:  2014-10       Impact factor: 54.908

7.  Role of aggregated human growth hormone (hGH) in development of antibodies to hGH.

Authors:  W V Moore; P Leppert
Journal:  J Clin Endocrinol Metab       Date:  1980-10       Impact factor: 5.958

8.  Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

Authors:  Paul M Ridker; Jean-Claude Tardif; Pierre Amarenco; William Duggan; Robert J Glynn; J Wouter Jukema; John J P Kastelein; Albert M Kim; Wolfgang Koenig; Steven Nissen; James Revkin; Lynda M Rose; Raul D Santos; Pamela F Schwartz; Charles L Shear; Carla Yunis
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

9.  Interferon immunogenicity: technical evaluation of interferon-alpha 2a.

Authors:  E Hochuli
Journal:  J Interferon Cytokine Res       Date:  1997-07       Impact factor: 2.607

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more
  2 in total

1.  Oil-Immersion Flow Imaging Microscopy for Quantification and Morphological Characterization of Submicron Particles in Biopharmaceuticals.

Authors:  Nils Krause; Sebastian Kuhn; Erik Frotscher; Felix Nikels; Andrea Hawe; Patrick Garidel; Tim Menzen
Journal:  AAPS J       Date:  2021-01-04       Impact factor: 4.009

2.  Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates.

Authors:  Michael D Swanson; Shantel Rios; Sarita Mittal; George Soder; Vibha Jawa
Journal:  Front Immunol       Date:  2022-07-27       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.